Neurogenes Breakthrough in Rett Syndrome Gene Therapy Trial Expansion and Accelerated Enrollment Plans
Neurogene has achieved a major breakthrough in its clinical trial for gene therapy targeting Rett syndrome. The company recently announced ...
Tag: NGNE
Analyst Recommends Buying Neurogene Stock A Promising Outlook for Investors
On January 17, 2024, Mitchell Kapoor, an analyst at HC Wainwright & Co., expressed a favorable stance on Neurogene (NASDAQ:NGNE), ...
Don't Miss It
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
